Comparative Pharmacokinetics and Bioequivalence Evaluation of Two Formulations of Pramipexole Dihydrochloride Extended-Release Tablets in Healthy Chinese Subjects Under Fasted and Fed States: A Randomized, Open-Label, Single-Dose, Two-Period Crossover Clinical Trial

BACKGROUND: Pramipexole dihydrochloride extended-release tablet is a novel long-acting form of non-ergot dopamine agonist indicated as one of main therapeutic approaches for Parkinson’s disease. However, pharmacokinetic properties of extended-release pramipexole in healthy Chinese subjects remain un...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ling, Zhang, Liangliang, Luo, Zhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439801/
https://www.ncbi.nlm.nih.gov/pubmed/37600497
http://dx.doi.org/10.2147/DDDT.S421449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439801/
https://www.ncbi.nlm.nih.gov/pubmed/37600497
http://dx.doi.org/10.2147/DDDT.S421449

Ejemplares similares